Revenue from Contracts with Customers

Revenue Disaggregation

The following table presents the Company’s net sales by therapeutic franchise for each of our reportable segments for the years ended December 31, 2018, 2017, and 2016:



(In millions)	North America		Europe		Rest of World		Total
Year Ended December 31, 2018
Central Nervous System & Anesthesia	$	718.5	$	877.5	$	340.7	$	1,936.7
Infectious Disease	260.8		441.8		826.4		1,529.0
Respiratory & Allergy	643.2		399.9		208.9		1,252.0
Cardiovascular	342.4		567.9		170.6		1,080.9
Gastroenterology	136.4		614.0		364.7		1,115.1
Diabetes & Metabolism	416.5		252.3		121.3		790.1
Dermatology	352.2		330.6		95.8		778.6
Women’s Health	350.7		253.2		104.4		708.3
Oncology	543.4		78.4		137.1		758.9
Immunology	49.5		18.7		38.6		106.8
Other ⁽¹⁾	282.0		323.0		607.3		1,212.3
Total	$	4,095.6	$	4,157.3	$	3,015.8	$	11,268.7



(In millions)	North America		Europe		Rest of World		Total
Year Ended December 31, 2017
Central Nervous System & Anesthesia	$	1,057.1	$	862.7	$	317.0	$	2,236.8
Infectious Disease	200.0		343.2		921.7		1,464.9
Respiratory & Allergy	709.8		446.3		206.2		1,362.3
Cardiovascular	454.5		579.8		170.3		1,204.6
Gastroenterology	183.5		581.0		357.9		1,122.4
Diabetes & Metabolism	577.7		266.2		103.6		947.5
Dermatology	529.4		295.3		106.0		930.7
Women’s Health	331.2		282.7		94.4		708.3
Oncology	487.4		71.2		148.6		707.2
Immunology	83.5		10.3		37.6		131.4
Other ⁽¹⁾	355.5		219.6		368.8		943.9
Total	$	4,969.6	$	3,958.3	$	2,832.1	$	11,760.0



(In millions)	North America		Europe		Rest of World		Total
Year Ended December 31, 2016
Central Nervous System & Anesthesia	$	1,105.0	$	699.5	$	198.9	$	2,003.4
Infectious Disease	184.0		270.4		884.0		1,338.4
Respiratory & Allergy	1,348.1		261.4		198.2		1,807.7
Cardiovascular	564.3		473.5		129.6		1,167.4
Gastroenterology	244.5		485.1		293.8		1,023.4
Diabetes & Metabolism	638.3		237.7		95.1		971.1
Dermatology	207.8		134.6		53.8		396.2
Women’s Health	367.9		151.4		70.9		590.2
Oncology	613.6		53.0		120.1		786.7
Immunology	93.6		8.2		32.1		133.9
Other ⁽¹⁾	262.4		179.0		307.3		748.7
Total	$	5,629.5	$	2,953.8	$	2,383.8	$	10,967.1

____________


⁽¹⁾	Other consists of numerous therapeutic franchises, none of which individually exceeds 5% of consolidated net sales.

Variable Consideration

The following table presents a reconciliation of gross sales to net sales by each significant category of variable consideration during the years ended December 31, 2018, 2017 and 2016, respectively:



	Year Ended December 31,
(In millions)	2018			2017			2016
Gross sales	$	19,588.1		$	22,206.1		$	21,058.9
Gross to net adjustments:
Chargebacks	(3,352.2		)	(4,239.5		)	(4,277.9		)
Rebates, promotional programs and other sales allowances	(4,235.6		)	(5,281.1		)	(5,147.9		)
Returns	(261.6		)	(390.7		)	(301.7		)
Governmental rebate programs	(470.0		)	(534.8		)	(364.3		)
Total gross to net adjustments	$	(8,319.4	)	$	(10,446.1	)	$	(10,091.8	)
Net sales	$	11,268.7		$	11,760.0		$	10,967.1

The following is a rollforward of the categories of variable consideration during 2018:



(In millions)	Balance at December 31, 2017		Current Provision Related to Sales Made in the Current Period		Checks/ Credits Issued to Third Parties			Effects of Foreign Exchange			Balance at December 31, 2018
Chargebacks	$	574.3	$	3,352.2	$	(3,447.1	)	$	(1.2	)	$	478.2
Rebates, promotional programs and other sales allowances	1,508.1		4,235.6		(4,526.0		)	(15.3		)	1,202.4
Returns	472.5		261.6		(292.1		)	(2.5		)	439.5
Governmental rebate programs	240.3		470.0		(486.6		)	(1.5		)	222.2
Total	$	2,795.2	$	8,319.4	$	(8,751.8	)	$	(20.5	)	$	2,342.3

Accruals for these provisions are presented in the Consolidated Financial Statements as reductions in determining net revenues and in accounts receivable and other current liabilities. Accounts receivable are presented net of allowances relating to these provisions, which were comprised of the following at December 31, 2018 and 2017, respectively:



(In millions)	December 31, 2018		December 31, 2017
Accounts receivable	$	1,715.6	$	1,977.2
Other current liabilities	626.7		818.0
Total	$	2,342.3	$	2,795.2

We have not made and do not anticipate making any significant changes to the methodologies that we use to measure provisions for variable consideration; however, the balances within these reserves can fluctuate significantly through the consistent application of our methodologies. Historically, we have not recorded in any current period any material amounts related to adjustments made to prior period reserves.